Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Endocrine Treatment Compared to Endocrine Treatment Alone, in Postmenopausal Women With Advanced or Metastatic Cancer With Indication of Hormonotherapy as First-line Treatment

Trial Profile

Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Endocrine Treatment Compared to Endocrine Treatment Alone, in Postmenopausal Women With Advanced or Metastatic Cancer With Indication of Hormonotherapy as First-line Treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Fulvestrant; Letrozole
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LEA
  • Most Recent Events

    • 06 Jun 2017 Results of pooled-analysis (n=749) using data from two randomized trials (LEA and CALGB 40503), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 11 Oct 2016 Results evaluating role of two biomarkers, ACE and CXCL10 as prognostic and/or predictive biomarkers of benefit to bevacizumab in the first line metastatic disease presented at the 41st European Society for Medical Oncology Congress
    • 12 Dec 2015 Results of predictors of outcome and benefit analysis of 103 patients were presented at the 38th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top